Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

FDA clearance expands partnered molecular glue pipeline Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need HAMBURG, Germany, Nov. 19, 2026 /PRNewswire/ — Evotec SE (NASDAQ: EVO)…

About the Author

has written 42680 stories on this site.

Copyright © 2010 Business and Corporate News.